结缔组织病：系统性硬化症：超越局限型和弥漫型亚类？
Connective tissue diseases: systemic sclerosis: beyond limited and diffuse subsets?
机构信息
Feinberg School of Medicine, Division of Rheumatology and Northwestern Scleroderma Program Northwestern University, 240 East Huron Street, Chicago, IL 60657, USA.
出版信息
Nat Rev Rheumatol. 2014 Apr;10(4):200-2. doi: 10.1038/nrrheum.2014.22. Epub 2014 Feb 18.
Abstract
Patients with systemic sclerosis present with varying clinical features, have different responses to therapy, and end up with different outcomes. Categorizing patients improves disease management. A new study now proposes that patients with systemic sclerosis and overlapping features of another connective tissue disease might form a distinct disease subset.
摘要
系统性硬化症患者具有不同的临床表现、对治疗的反应不同，最终结局也不同。对患者进行分类有助于疾病管理。一项新的研究现在提出，具有重叠结缔组织病特征的系统性硬化症患者可能构成一个独特的疾病亚组。
相似文献
1
Connective tissue diseases: systemic sclerosis: beyond limited and diffuse subsets?结缔组织病：系统性硬化症：超越局限型和弥漫型亚类？
Nat Rev Rheumatol. 2014 Apr;10(4):200-2. doi: 10.1038/nrrheum.2014.22. Epub 2014 Feb 18.
2
[What's new in connective tissue diseases?].
Dtsch Med Wochenschr. 2013 Apr;138(14):728-31. doi: 10.1055/s-0032-1332871. Epub 2013 Mar 26.
3
Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison.干燥综合征和其他罕见且复杂的结缔组织疾病：一种有趣的关联。
Clin Exp Rheumatol. 2022 May;40 Suppl 134(5):103-112. doi: 10.55563/clinexprheumatol/3y0hqs. Epub 2022 Mar 21.
4
[Systemic sclerosis--clinical course and treatment possibilities].[系统性硬化症——临床病程及治疗可能性]
Przegl Lek. 2005;62(12):1538-41.
5
Connective tissue disease: Reflections on the EULAR recommendations for the treatment of systemic sclerosis.结缔组织病：关于欧洲抗风湿病联盟系统性硬化症治疗建议的思考
Nat Rev Rheumatol. 2017 Mar;13(3):134-136. doi: 10.1038/nrrheum.2016.212. Epub 2017 Jan 5.
6
Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD).对665例匈牙利未分化结缔组织病（UCTD）患者的五年随访。
Clin Exp Rheumatol. 2003 May-Jun;21(3):313-20.
7
Raynaud's phenomenon.雷诺现象。
Best Pract Res Clin Rheumatol. 2020 Feb;34(1):101474. doi: 10.1016/j.berh.2019.101474. Epub 2020 Jan 29.
8
[Undifferentiated connective tissue disease].[未分化结缔组织病]
Orv Hetil. 2009 May 10;150(19):867-72. doi: 10.1556/OH.2009.28610.
9
Connective tissue diseases: New criteria improve recognition of early systemic sclerosis.结缔组织病：新的标准提高了对早期系统性硬化症的识别。
Nat Rev Rheumatol. 2015 Jan;11(1):3-4. doi: 10.1038/nrrheum.2014.191. Epub 2014 Nov 11.
10
Systemic sclerosis sine scleroderma: is it always the same disease? Report of three patients and discussion.无硬皮病的系统性硬化症：它总是同一种疾病吗？三例病例报告及讨论
Rheumatol Int. 2002 Aug;22(4):170-2. doi: 10.1007/s00296-002-0222-y. Epub 2002 Jul 2.
引用本文的文献
1
Nanofat and lipofilling for cutaneous fibrosis in scleroderma: Current evidence and future directions.纳米脂肪和脂肪填充治疗硬皮病皮肤纤维化：当前证据与未来方向
J Scleroderma Relat Disord. 2025 May 15:23971983251341502. doi: 10.1177/23971983251341502.
2
Elevated Circulating Levels of Gut Microbe-Derived Trimethylamine -Oxide Are Associated with Systemic Sclerosis.肠道微生物衍生的氧化三甲胺循环水平升高与系统性硬化症相关。
J Clin Med. 2024 Oct 8;13(19):5984. doi: 10.3390/jcm13195984.
3
Peripheral and ocular microvascular alterations in systemic sclerosis: observations from capillaroscopic assessments, perfusion peripheral analysis, and optical coherence tomography angiography.系统性硬化症的外周和眼部微血管改变：从毛细血管镜评估、血流外周分析和光相干断层扫描血管造影观察到的结果。
Rheumatol Int. 2024 Jan;44(1):107-118. doi: 10.1007/s00296-023-05495-z. Epub 2023 Nov 17.
4
A Multidisciplinary Approach as a Goal for the Management of Complications in Systemic Scleroderma: A Literature Review and Case Scenario.一种多学科方法作为系统性硬化症并发症管理的目标：文献综述与病例分析
Diagnostics (Basel). 2023 Oct 28;13(21):3332. doi: 10.3390/diagnostics13213332.
5
Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database.无皮肤硬化系统性硬皮病患者的皮肤表现、临床特征和预后：来自国际 EUSTAR 数据库的数据。
JAMA Dermatol. 2023 Aug 1;159(8):837-847. doi: 10.1001/jamadermatol.2023.1729.
6
Pharmacological inhibition of TAK1 prevents and induces regression of experimental organ fibrosis.TAK1 的药理学抑制可预防和诱导实验性器官纤维化的消退。
JCI Insight. 2023 Jul 24;8(14):e165358. doi: 10.1172/jci.insight.165358.
7
The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib.JAK/STAT信号通路在系统性硬化症中被激活，而托法替布可有效作用于该通路。
J Scleroderma Relat Disord. 2020 Feb;5(1):40-50. doi: 10.1177/2397198319865367. Epub 2019 Aug 7.
8
Unenhanced Cardiac Magnetic Resonance may improve detection and prognostication of an occult heart involvement in asymptomatic patients with systemic sclerosis.心脏磁共振平扫可能提高隐匿性系统性硬化症无症状患者心脏受累的检出率和预测预后。
Sci Rep. 2022 Mar 24;12(1):5125. doi: 10.1038/s41598-022-09064-5.
9
Engineering Advanced In Vitro Models of Systemic Sclerosis for Drug Discovery and Development.工程化全身性硬皮病的体外先进模型用于药物发现和开发。
Adv Biol (Weinh). 2021 Apr;5(4):e2000168. doi: 10.1002/adbi.202000168. Epub 2021 Feb 15.
10
Systemic sclerosis: To subset or not to subset, that is the question.系统性硬化症：是否进行亚组分析，这是个问题。
Eur J Rheumatol. 2020 Oct;7(Suppl 3):S222-S227. doi: 10.5152/eurjrheum.2020.19116. Epub 2020 Jul 6.
本文引用的文献
1
Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis.系统性硬化症重叠综合征的疾病进展与局限性和弥漫性皮肤型系统性硬化症显著不同。
Ann Rheum Dis. 2015 Apr;74(4):730-7. doi: 10.1136/annrheumdis-2013-204487. Epub 2014 Jan 3.
2
Association of the autoimmune disease scleroderma with an immunologic response to cancer.硬皮病等自身免疫性疾病与癌症免疫反应之间的关联。
Science. 2014 Jan 10;343(6167):152-7. doi: 10.1126/science.1246886. Epub 2013 Dec 5.
3
Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis.皮肤中的分子特征与霉酚酸酯治疗系统性硬皮病时的临床改善相关。
J Invest Dermatol. 2013 Aug;133(8):1979-89. doi: 10.1038/jid.2013.130. Epub 2013 Mar 14.
4
Systemic sclerosis sine scleroderma: distinct features in a large Brazilian cohort.系统性硬皮病无硬皮病：巴西大队列中的独特特征。
Rheumatology (Oxford). 2013 Aug;52(8):1520-4. doi: 10.1093/rheumatology/ket163. Epub 2013 May 9.
5
Clinical and serological hallmarks of systemic sclerosis overlap syndromes.系统性硬化症重叠综合征的临床和血清学特征。
J Rheumatol. 2011 Nov;38(11):2406-9. doi: 10.3899/jrheum.101248. Epub 2011 Aug 15.
6
Antinuclear antibodies and clinical associations in a british cohort with limited cutaneous systemic sclerosis.抗核抗体与局限性皮肤型系统性硬皮病英国队列中的临床相关性。
J Rheumatol. 2011 Apr;38(4):702-5. doi: 10.3899/jrheum.100754. Epub 2011 Jan 15.
7
Molecular subsets in the gene expression signatures of scleroderma skin.硬皮病皮肤基因表达特征中的分子亚群。
PLoS One. 2008 Jul 16;3(7):e2696. doi: 10.1371/journal.pone.0002696.
8
Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis.127名法国和247名美国成年系统性硬化症患者的疾病亚组、抗核抗体谱及临床特征
J Rheumatol. 2007 Jan;34(1):104-9. Epub 2006 Nov 15.
9
Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients.无硬皮病的系统性硬化症：48例患者的人口统计学、临床和血清学特征及生存率
Arthritis Rheum. 2000 Feb;43(2):444-51. doi: 10.1002/1529-0131(200002)43:2<444::AID-ANR27>3.0.CO;2-G.
10
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.硬皮病（系统性硬化症）：分类、亚型及发病机制
J Rheumatol. 1988 Feb;15(2):202-5.
Zotero 插件